In this study, MMF reduced serum CD44 and VCAM-1 levels compared to vehicle-treated mice, further highlighting the putative role of serum CD44 as a potential biomarker for disease activity and treatment efficacy in human and mice with active LN. This evidence concerns the gene VCAM1 and lobular neoplasia.